HomeBUSINESS
BUSINESS

Eisai Bags Up-to-US$5.76 Billion Lenvima Alliance with Merck
(Mar.9.2018)

Eisai CEO Haruo Naito
Eisai has forged a strategic collaboration with Merck for its multi-kinase inhibitor Lenvima (lenvatinib) and its combination therapy with the US giant’s PD-1 inhibitor Keytruda (pembrolizumab) in a deal that could bring the Japanese company up to US$5.76 billion ...
(LOG IN FOR FULL STORY)